Drive Wealth Management LLC Invests $104,000 in Calidi Biotherapeutics, Inc. (NYSE:CLDI)

Drive Wealth Management LLC acquired a new position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 90,000 shares of the company’s stock, valued at approximately $104,000.

Separately, CPR Investments Inc. raised its stake in shares of Calidi Biotherapeutics by 80.4% in the fourth quarter. CPR Investments Inc. now owns 101,000 shares of the company’s stock worth $116,000 after purchasing an additional 45,000 shares during the last quarter. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Trading Down 0.4 %

Shares of CLDI stock opened at $0.66 on Wednesday. The stock has a 50 day moving average of $1.51 and a 200 day moving average of $1.43. Calidi Biotherapeutics, Inc. has a twelve month low of $0.62 and a twelve month high of $16.80.

Calidi Biotherapeutics (NYSE:CLDI) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.20. On average, equities research analysts forecast that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current fiscal year.

Calidi Biotherapeutics Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.